Recommendations for the use of parenteral methotrexate in rheumatic diseases

被引：11

作者：

Tornero Molina, Jesus ^{[1
]}

Calvo Alen, Jaime ^{[2
]}

Ballina, Javier ^{[3
]}

Angeles Belmonte, Maria ^{[4
]}

Blanco, Francisco J. ^{[5
]}

Angel Caracuel, Miguel ^{[6
]}

Carbonell, Jordi ^{[7
]}

Corominas, Hector ^{[8
]}

Chamizo, Eugenio ^{[9
]}

Hidalgo, Cristina ^{[10
]}

Roman Ivorra, Jose ^{[11
]}

Luis Marenco, Jose ^{[12
]}

Moreno Muelas, Jose Vicente ^{[13
]}

Munoz-Fernandez, Santiago ^{[14
]}

Nolla, Joan M. ^{[15
]}

Perez, Trinidad ^{[16
]}

Sanmarti, Raimon ^{[17
]}

Trenor, Pilar ^{[18
]}

Urrego, Claudia ^{[19
]}

Vidal, Javier ^{[1
]}

Gomez de Salazar, Jose Rosas ^{[20
]}

机构：

[1] Hosp Guadalajara, Serv Reumatol, Guadalajara, Spain

[2] Hosp Univ Araba, Vitoria, Spain

[3] Hosp Univ Cent Asturias, Oviedo, Spain

[4] Hosp Reg Univ Malaga, Malaga, Spain

[5] CHUAC, La Coruna, Spain

[6] Hosp Univ Reina Sofia, Cordoba, Spain

[7] Hosp del Mar, Barcelona, Spain

[8] Hosp St Joan Despi Moises Broggi, Barcelona, Spain

[9] Hosp Merida, Badajoz, Spain

[10] Complejo Asistencial Univ Salamanca, Salamanca, Spain

[11] Hosp Univ & Politecn La Fe, Valencia, Spain

[12] Hosp Virgen de Valme, Seville, Spain

[13] Hosp Univ Vall dHebron, Barcelona, Spain

[14] Univ Europea Madrid, Hosp Univ Infanta Sofia, Madrid, Spain

[15] Hosp Univ Bellvitge, Barcelona, Spain

[16] Hosp Leon, Leon, Spain

[17] Hosp Univ Clin, Barcelona, Spain

[18] Hosp Clin Valencia, Valencia, Spain

[19] Complejo Asistencial Segovia, ,, Segovia, Spain

[20] Hosp Marina Alta de la Villajoyosa, Alicante, Spain

来源：

REUMATOLOGIA CLINICA | 2018年 / 14卷 / 03期

关键词：

Methotrexate; Parenteral; Rheumatic diseases;

D O I：

10.1016/j.reuma.2016.12.001

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective: To develop recommendations for the use of parenteral methotrexate (MTX) in rheumatic diseases, mainly rheumatoid arthritis, based on best evidence and experience.& para;& para;Methods: A group of 21 experts on parenteral MTX use was selected. The coordinator formulated 13 questions about parenteral MTX (indications, efficacy, safety and cost-effectiveness). A systematic review was conducted to answer the questions. Using this information, inclusion and exclusion criteria were established, as were the search strategies (involving Medline, EMBASE and the Cochrane Library). Three different reviewers selected the articles. Evidence tables were created. Abstracts from the European League Against Rheumatism (EULAR) and American College of Rheumatology (ACR) were evaluated. Based on this evidence, the coordinator proposed preliminary recommendations that the experts discussed and voted in a nominal group meeting. The level of evidence and grade of recommendation were established using the Oxford Center for Evidence-Based Medicine and the level of agreement with the Delphi technique (2 rounds). Agreement was established if at least 80% of the experts voted yes (yes/no).& para;& para;Results: Most of the evidence involved rheumatoid arthritis. A total of 13 preliminary recommendations on the use of parenteral MTX were proposed; 11 of them were accepted. Two of the 13 were not voted and are commented on in the main text.& para;& para;Conclusions: The manuscript aims to solve frequent questions and help in decision-making strategies when treating patients with parenteral MTX. (C) 2016 Elsevier Espana, S.L.U. and Sociedad Espanola de Reumatologia y Colegio Mexicano de Reumatologia. All rights reserved.

引用

页码：142 / 149

页数：8

共 52 条

[1]

Arthur AB, 1999, J RHEUMATOL, V26, P302

[2] Are switches from oral to subcutaneous methotrexate or addition of ciclosporin to methotrexate useful steps in a tight control treatment strategy for rheumatoid arthritis? A post hoc analysis of the CAMERA study [J].

Bakker, M. F. ;

Jacobs, J. W. G. ;

Welsing, P. M. J. ;

van der Werf, J. H. ;

Linn-Rasker, S. P. ;

van der Veen, M. J. ;

Lafeber, F. P. J. G. ;

Bijlsma, J. W. J. .

ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (10) :1849-1852

[3] Use of parenteral methotrexate significantly reduces the need for biological therapy [J].

Bharadwaj, A. ;

Agrawal, S. ;

Batley, M. ;

Hammond, A. .

RHEUMATOLOGY, 2008, 47 (02) :222-222

[4] Parenteral methotrexate should be given before biological therapy [J].

Bingham, SJ ;

Buch, MH ;

Lindsay, S ;

Pollard, A ;

White, J ;

Emery, P .

RHEUMATOLOGY, 2003, 42 (08) :1009-1010

[5]

Black N, 1999, J Health Serv Res Policy, V4, P236

[6]

Borman Pinar, 2014, Open Rheumatol J, V8, P18, DOI 10.2174/1874312901408010018

[7]

Branco JC, 2016, ADV THER

[8] Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis [J].

Braun, J. ;

Kaestner, P. ;

Flaxenberg, P. ;

Waehrisch, J. ;

Hanke, P. ;

Demary, W. ;

von Hinueber, U. ;

Rockwitz, K. ;

Heitz, W. ;

Pichlmeier, U. ;

Guimbal-Schmolck, C. ;

Brandt, A. .

ARTHRITIS AND RHEUMATISM, 2008, 58 (01) :73-81

[9] PHARMACOKINETICS OF METHOTREXATE ADMINISTERED BY INTRAMUSCULAR AND SUBCUTANEOUS INJECTIONS IN PATIENTS WITH RHEUMATOID-ARTHRITIS [J].

BROOKS, PJ ;

SPRUILL, WJ ;

PARISH, RC ;

BIRCHMORE, DA .

ARTHRITIS AND RHEUMATISM, 1990, 33 (01) :91-94

[10] Intramuscular methotrexate in inflammatory rheumatic disease [J].

Burbage, G ;

Gupta, R ;

Lim, K .

ANNALS OF THE RHEUMATIC DISEASES, 2001, 60 (12) :1156-1156

← 1 2 3 4 5 6 →